

**Department of Vermont Health Access
High-Investment Carve-Out Drugs List
7/1/2024**

| HCPCS Code | Drug Name | Generic Drug Name |
|------------|------------|-----------------------------------|
| J3399 | Zolgensma® | Onasemnogene Abeparvovec-xioi |
| J2326 | Spinraza® | Nusinersen |
| Q2042 | Kymriah® | Tisagenlecleucel |
| Q2041 | Yescarta® | Axicabtagene Ciloleucel |
| Q2053 | Tecartus™ | Brexucabtagene Autoleucel |
| Q2055 | Abecma® | Idecabtagene Vicleucel |
| Q2056 | Carvykti® | Ciltacabtagene Autoleucel |
| Q2054 | Breyanzi® | Lisocabtagene Maraleucel |
| J1411 | Hemgenix® | Etranacogene Dezaparvovec-drlb |
| J1412 | Roctavian™ | Valoctocogene Roxaparvovec-rvox |
| J1413 | Elevidys® | Delandistrogene Moxeparvovec-rokl |
| J3393 | Zynteglo™ | Betibeglogene Autotemcel |

All strengths and formulations of the listed drugs are included

Global Commitment Register (GCR 22-002)

https://humanservices.vermont.gov/sites/ahsnew/files/doc_library/22-002-Proposed-GCR-High-Investment-Drugs-SPA.pdf.